1. Clinical Outcomes of Comparison Between Type III Coronary Artery Perforation (CAP) and non-CAP Acute Coronary Syndrome Patients During 3-Year Follow-up.
- Author
-
Yildiz, Bekir S., Gunduz, Ramazan, Ozgur, Su, Cizgici, Ahmet Y., and Ozdemir, Ibrahim H.
- Subjects
- *
MYOCARDIAL infarction risk factors , *HEMORRHAGE risk factors , *CORONARY artery injuries , *THROMBOSIS risk factors , *RISK assessment , *HOSPITAL mortality , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *SURGICAL stents , *ACUTE coronary syndrome , *LOG-rank test , *CORONARY artery bypass , *PERCUTANEOUS coronary intervention , *CASE-control method , *RESEARCH , *CONFIDENCE intervals , *TIME , *PATIENT aftercare , *EVALUATION - Abstract
Coronary artery perforation (CAP) is a potentially fatal complication of percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS). This study aimed to investigate in-hospital, 1-year, and 3-year clinical outcomes of type III CAP during PCI in patients with ACS. The study retrospectively evaluated 118 patients with CAP and 43,226 case-control patients. Clinical, angiographic, and procedural characteristics, management, and outcomes were analyzed retrospectively at 1-year and 3-year follow-ups. The mean age of the patients was 66.5 ± 11.9 years (61.8% males). There was no significant difference in hospital mortality between the type III CAP and non-CAP groups. The all-cause mortality was 33.3% in the CAP group vs 1.8% in the non-CAP group at 1 year, and 28.3% in CAP group vs 6.9% in non-CAP group at 3 years (p =.001 for both comparisons). The procedural, clinical, and 1 and 3-year outcomes of type III CAP showed a relatively high risk of myocardial infarction, coronary artery bypass graft, cerebrovascular event, stent thrombosis, and major bleeding at the 1 and 3-year follow-ups. In addition, non-CAP ACS patients had better survival (log-rank: p <.001, 34.29 months 95% Confidence Interval [33.58–35.00]) than type III CAP ACS patients (29.53 months 95% Confidence Interval [27.28–31.78]) at the 3-year follow-up visit. [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF